Kite, a subsidiary of Gilead (NASDAQ: GILD), has announced a significant enhancement in the treatment process for its CAR T-cell therapy, Yescarta (axicabtagene ciloleucel). The median turnaround time (TAT) for this life-saving therapy is set to decrease from 16 days to 14 within the United States, following an approval by the US Food and Drug Administration (FDA) for an optimized manufacturing process.
This development is particularly beneficial for patients who rely on timely access to such therapies. Yescarta, which has demonstrated a 96% manufacturing success rate, has already been administered to over 17,700 patients worldwide. The treatment is available through a network of more than 400 authorized treatment centers (ATCs) globally, highlighting Kite’s commitment to expanding access to innovative cancer treatments.- Flcube.com
